**Technology Advisory Committee B Interests Register**

**Tofacitinib for treating active ankylosing spondylitis [ID3865]**

**Publication Date: 18/10/2023**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Name | Role with NICE | Type of interest | Description of interest | Interest  arose | Interest  declared | Interest  ceased | Comments |
| Dr James Fotheringham | Committee Member | Direct Financial | Participated in an Advisory Board meeting for Novartis, about risk prediction tools in kidney transplantation, and honorarium was paid to directly to himself. | 22/05/22 | 09/06/22 |  | It was agreed this this declaration would not prevent Dr Fotheringham from participating in this discussion. |
| Professor Nick Latimer | Committee Member | Direct Financial | In October 2021, he gave Novartis staff a training session on survival analysis. This was not product or appraisal specific and was about methods. Novartis are listed as the manufacturer of a comparator. | 19/05/22 | 09/06/22 |  | It was agreed that this declaration would not prevent Professor Latimer from taking part in this discussion. |
| Mr Peter Wheatly-Price | Committee Member | Direct Professional and Personal interest | Peter has lived with Ankylosing Spondylitis since aged 23 and have previously been treated with etanercept and adalumimab and is currently on golumimab. He had also previously served for 12 years as a trustee for the patient organisation (National Ankylosing Spondylitis Society now National Axial Spondyloarthritis Society.) He is currently a member but not active in any way. | 20/05/22 | 09/06/22 |  | It was agreed that this declaration would not prevent Peter Wheatley-Price from participating in this discussion. |
| Ms Frances Reid | Patient Expert |  |  |  |  |  |  |
| Dr Raj Sengupta | Clinical Expert | Direct Financial | Received honoraria, grants and conference support from Abbvie, Biogen, Celgene, Lilly, Novartis, Roche and UCB. | 18/10/21 | 09/06/22 |  | It was agreed that this declaration would not prevent Dr Sengupta from providing expert advice in this discussion. |